06 · PLAIN ANSWERS FROM THE STUDIES
BPC-157 TB-500 FAQ: what can the studies answer?
Each answer starts with what happened in animals or people. The unknowns stay clear. The blend still lacks a human study.
What are the two parts, and what injuries were studied?
BPC-157 and TB-500 are the two named parts. Studies looked at tendons, ligaments, muscles, skin, and blood flow. Most work used rats or cells kept in dishes. No careful test gave both parts together.
What injuries was BPC-157 and TB-500 studied for?
BPC-157 work covered four kinds of rat injury: tendon, ligament, muscle, and skin wounds. TB-500 and Thymosin Beta-4 work watched repair cells move across wounds [1][5]. Most studies used rats or mice. None gave both blend parts together, so those findings can’t predict your healing.
Why do sellers call the pair Wolverine?
Sellers call the two-part blend Wolverine. BPC-157 is a lab-made 15-amino-acid chain [1][3]. TB-500 is a shorter piece from Thymosin Beta-4. The nickname doesn’t make the blend an approved drug.
What exactly are BPC-157 and TB-500?
BPC-157 came from stomach-protein work [1]. TB-500 is a lab-made part of Thymosin Beta-4 [3][8]. Both are short protein chains called peptides. The Wolverine product combines parts from separate lines of research.
How do BPC-157 and TB-500 differ?
BPC-157 is a 15-amino-acid chain [1][2]. TB-500 is a 7-amino-acid section of Thymosin Beta-4 [3]. The first part affected blood flow near injured rat tissue. The second affected a protein that cells need for movement.
Why do sellers combine the parts, and is there proof?
Sellers join two findings from separate studies. One part may aid blood flow. The other may guide repair cells into place. Researchers have not checked whether those effects add together in a blend.
Why are BPC-157 and TB-500 sold together?
BPC-157 restored blood flow in damaged rat tissue [2]. TB-500 may guide repair cells toward the hurt spot [3]. Sellers say those effects fit together. A careful study hasn’t tested that idea.
Did BPC-157 and TB-500 work better together?
No published study set a ratio or found a larger shared effect. A 2025 review counted 36 BPC-157 studies, with only one in people [9]. Useful human safety facts were missing. TB-500 and the blend were not tested, so these findings cannot guide a treatment choice.
Have BPC-157 and TB-500 been tested together in people?
No human study has tested the two parts together. Three small early studies tested BPC-157 alone. A first human safety test, called Phase 1, tested full Thymosin Beta-4 [4][8]. It did not test short TB-500, so the blend’s safety and benefit remain unknown.
How did TB-500 and Thymosin Beta-4 affect cells?
Actin is a cell protein used during shape changes. A dish test found a 1:1 hold between TB-500 and actin [3]. One short protein part joined with a single actin part. The lab work measured no healing, and most other findings used full Thymosin Beta-4 [4].
How did BPC-157 act differently from TB-500?
More new blood vessels appeared with BPC-157 [1][2]. The substance made the tendon cells more responsive to growth hormone. This hormone helps tissue grow. TB-500 held actin inside cells [3], but researchers never tested both effects together.
Did BPC-157 and TB-500 both support new blood vessels?
Both parts supported new blood vessels in animals or cells in dishes. BPC-157 restored blood in injured rat muscle [2]. Thymosin Beta-4 helped blood-vessel cells move in old rodents [7]. No blend study measured that result.
What changed in rat wounds, tendons, and muscles?
Rat wound studies gave the strongest numbers. Tendon and muscle studies gave other useful findings. Each study tested only one part. None of these results predicts what happens in your body.
Does BPC-157 TB-500 help a wound close?
Compared with untreated rat wounds, full Thymosin Beta-4 raised new skin cover by about 42% at 4 days. The increase reached 61% at 7 days [5][1]. BPC-157 helped other rat wounds in separate tests. No test showed that the blend closes a human wound.
Does BPC-157 TB-500 help tendons or ligaments?
BPC-157 helped cut Achilles tendons and knee ligaments in rats. It also helped a tendon join bone [1][4]. TB-500 and Thymosin Beta-4 helped rat knee ligaments. No blend study can predict what your tendon will do.
Does BPC-157 and TB-500 help injured muscle?
BPC-157 helped crushed rat calf muscle recover. A 2025 study also followed thigh muscle joining bone [1][4]. With Thymosin Beta-4, young muscle cells moved toward the hurt spot. No human blend study checked muscle healing.
Which amounts and forms appeared in the studies?
The amounts came from animal work. Study staff prepared and gave each part alone. The figures do not set a human blend dose. No blend schedule has been proved.
Could animal studies set a BPC-157 and TB-500 weekly amount?
No weekly blend amount has proof. For each kilogram of body weight, BPC-157 tests gave animals 10 millionths or 10 billionths of a gram. One six-month TB-500 evidence test gave full Thymosin Beta-4 at 150 millionths of a gram twice weekly [1][4]. Animal figures cannot set your weekly amount.
Did BPC-157 and TB-500 leave animals at the same speed?
Human work gives no sound answer for either short protein. BPC-157 took under 30 minutes in rat and dog work. Full Thymosin Beta-4 lasted longer at higher amounts [4]. Short TB-500 was not measured that way.
Do BPC-157 / TB-500 10mg mixing directions show safety?
Both short proteins may come as powders dried by freezing. Sellers describe adding germ-free water and keeping the mixture cold [1]. Those are seller directions, not a safety finding. A BPC-157:TB-500 label can’t prove what is inside.
How often were BPC-157 and TB-500 given?
No test proved how often the blend belongs in a shot. Each animal study chose its own times. One six-month mouse study gave Thymosin Beta-4 twice weekly, at 150 millionths of a gram [4]. A larger first amount lacks careful human proof.
Did a BPC-157 TB-500 test prove weeks on and off?
No study proved a blend cycle, meaning set weeks of use and time off. Some fixed vials list 10 mg plus 10 mg. One rat test gave 18 milligrams per kilogram of Thymosin Beta-4. The rats got no benefit [4], so the larger amount failed in that test.
Which safety questions still lack human answers?
No careful human study gives safety rates for the blend. These answers cover tumors, the heart, and long use. Full Thymosin Beta-4 produced most findings behind the concern. Rat tests cannot tell your personal risk.
What side effects are known for BPC-157 and TB-500?
No side effect has a measured human rate for the blend. A 2025 review found no useful human safety facts for BPC-157 [9]. Full Thymosin Beta-4 helped cells move and blood vessels grow [4]. Those findings raise a possible tumor concern but cannot count your risk.
Has TB-500 been shown to cause cancer?
No human study links cancer with this blend. Full Thymosin Beta-4 may help tumor cells move. It may also support growth of new blood vessels [4].
Those changes could aid tumor spread. Long human studies are missing, so the concern remains open. The finding does not mean the blend caused anyone's cancer.
What did heart studies find for TB-500?
Heart repair studies tested full Thymosin Beta-4. A first human safety test, called Phase 1, found people tolerated full Thymosin Beta-4 [4]. The report here does not say how many people were tested or for how long. A six-month mouse test found no better heart work, and short TB-500 lacks a human heart safety test.
What do federal and sport rules mean now?
One federal rule covers medicine mixed for one named patient. The federal pharmacy page explains the rule. Federal approval is a separate question. The sport testing group called WADA sets rules for tested athletes.
Are BPC-157 and TB-500 approved or allowed in tested sports?
FDA has approved neither part for people. Both went onto the Category 2 safety concern list during 2023 [12]. The sport testing group called WADA bars BPC-157 and Thymosin Beta-4, including TB-500. A tested athlete remains barred from both.
Does the Wolverine name make the blend legal?
The Wolverine name does not make either part an approved drug. No medical use for the blend has approval [12]. Both Category 2 listing requests are now withdrawn. That means those requests ended, while tested sport still bars both parts.
Can a pharmacy supply BPC-157?
The rules for compounding BPC-157 apply separately from any patient's prescription. BPC-157 entered Category 2 on September 29, 2023. The current FDA page labels its nomination withdrawn [12]. The July 23-24, 2026 review did not change the rule by itself [13].
What is FDA’s current status for Wolverine?
FDA's current table lists the BPC-157 and TB-500 nominations as withdrawn. Both now sit outside Category 2 [12]. The old requests ended without conferring drug approval or permission to compound either part. The July 2026 meeting took place, but a discussion alone cannot settle the compounding rules [13].